Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crizotinib + esomeprazole
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Crizotinib + esomeprazole is the coadministration of **crizotinib**, a small-molecule tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK), ROS1, and MET, and **esomeprazole**, a proton pump inhibitor (PPI) that reduces gastric acid secretion. Crizotinib is primarily used for ALK-positive and ROS1-positive metastatic non-small cell lung cancer. Esomeprazole is commonly used to treat acid-related disorders. The combination is studied due to possible pharmacokinetic interactions, as crizotinib has pH-dependent solubility and esomeprazole raises gastric pH. Studies show coadministration results in a modest ~10% decrease in total crizotinib exposure but no significant change in peak exposure or safety profile, and no dose adjustment is considered necessary[1][2][3].
- Brand names
- XalkoriNexium
- Other names
- crizotinib + esomeprazole
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)MST1R (Recepteur d'origine nantais)
Beyond the preview
Go deeper on crizotinib + esomeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crizotinib + esomeprazole.